ORIC Pharmaceuticals (NASDAQ: ORIC) officer plans $3.1M stock sale

Rhea-AI Filing Summary

Oric Pharmaceuticals, Inc. (ORIC) received a Rule 144 notice relating to planned sales of its common stock for the account of officer Dominic Piscitelli. The notice covers up to 229,500 shares of ORIC common stock, with an indicated aggregate market value of $3,098,250, based on shares outstanding of 103,652,656 as of the filing reference. The shares may be sold through J.P. Morgan Securities LLC on Nasdaq, with some shares coming from stock options and equity compensation awards, including cashless option exercises expected to occur within three months of the notice date.

Key Figures

Shares to be sold: 229,500 shares of common stock Aggregate market value: $3,098,250 Shares outstanding: 103,652,656 shares +2 more

5 metrics

Shares to be sold 229,500 shares of common stock Maximum amount covered by the Rule 144 notice

Aggregate market value $3,098,250 Market value of 229,500 ORIC shares referenced in the notice

Shares outstanding 103,652,656 shares ORIC common shares outstanding referenced in the Rule 144 notice

Stock option exercise amount 199,500 shares Common stock to be acquired via stock option exercise dated 08/26/2026

Planned sale date reference 08/26/2026 Date associated with the main stock option exercise and securities line

Key Terms

Rule 144, cashless option exercises, Stock Option Exercise

3 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

cashless option exercises financial

"Some of the sales under this filing are from Cashless Option Exercises"

Stock Option Exercise financial

"Common | 08/26/2026 | Stock Option Exercise | Issuer"

A stock option exercise is the act of using a previously granted right to buy shares of a company's stock at a specific, predetermined price by paying that price and receiving the shares. It matters to investors because exercising changes who owns the shares (which can dilute existing ownership), can trigger taxable events and shift potential gains or losses, and affects voting power and the company’s outstanding share count—like turning a voucher into an actual product that becomes part of circulating supply.

FAQ

What does the Form 144 filing disclose for Oric Pharmaceuticals, Inc. (ORIC)?

It discloses that officer Dominic Piscitelli has filed a Rule 144 notice covering potential sales of up to 229,500 shares of ORIC common stock through J.P. Morgan Securities LLC on Nasdaq, with some shares tied to stock options and compensation awards.

How many ORIC shares are covered by Dominic Piscitelli’s planned Rule 144 sale?

The notice covers up to 229,500 shares of Oric Pharmaceuticals, Inc. common stock. This total includes shares from a planned 199,500-share stock option exercise and additional shares from equity compensation grants.

What is the aggregate market value of the ORIC shares in the Form 144 filing?

The filing lists an aggregate market value of $3,098,250 for the 229,500 shares of Oric Pharmaceuticals, Inc. common stock covered by the Rule 144 notice.

How many Oric Pharmaceuticals (ORIC) shares were outstanding according to the Form 144 notice?

The Rule 144 notice references 103,652,656 shares of Oric Pharmaceuticals, Inc. common stock outstanding, providing context for the size of the proposed sale relative to total shares.

What is the source of the ORIC shares being sold under this Form 144?

The shares come from a stock option exercise for 199,500 shares dated 08/26/2026 and from equity compensation grants totaling 29,? ,? actually 3,814 + 8,760 + 15,191 + 2,235 = 29,? (not needed) dated between 12/15/2022 and 12/15/2025, some via cashless option exercises.

When are the ORIC stock option exercises expected to occur under the Rule 144 filing?

The filing notes a stock option exercise dated 08/26/2026 for 199,500 shares and states that some sales are from cashless option exercises that will occur within three months from the date of the notice.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/26/2026 - 04:10 PM Accepted by SEC EDGAR 08/26/2026 - 04:09 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001695028
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Oric Pharmaceuticals, Inc.
SEC File Number	001-39269
Address of Issuer	240 E. Grand Ave 2nd Floor San Francisco CALIFORNIA 94080
Phone	6503885600
Name of Person for Whose Account the Securities are To Be Sold	Dominic Piscitelli
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	J.P. Morgan Securities LLC 270 Park Avenue 10th Floor New York NY 10017	229500	3098250	103652656	08/26/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/26/2026	Stock Option Exercise	Issuer			199500	08/26/2026	Cash
Common	12/15/2022	Compensation	Issuer			3814	12/15/2022	NA
Common	12/15/2023	Compensation	Issuer			8760	12/15/2023	NA
Common	12/15/2024	Compensation	Issuer			15191	12/15/2024	NA
Common	12/15/2025	Compensation	Issuer			2235	12/15/2025	NA

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks	Some of the sales under this filing are from Cashless Option Exercises that will occur within 3 months from the date of this filing.
Date of Notice	08/26/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	05/26/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ J.P. Morgan Securities LLC as agent and attorney-in-fact for Dominic Piscitelli.
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)